Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations

Presented at EORTC 2014, Barcelona, Spain

A Vaslin, C Moulon, V Nicolas-Métral, A Menetrey, H Maby-El Hajjami, S Rigotti, C Zanna, G Vuagniaux

(1) Debiopharm International SA, Lausanne, Switzerland